Trabectedin

A complex structure that includes isoquinolines joined by a cyclic ester; it is a DNA-binding agent and guanine N2 alkylator derived from the marine tunicate, Ecteinascidia turbinata. Trabectedin is used for the treatment of advanced soft-tissue SARCOMA, after failure of ANTHRACYCLINES or IFOSFAMIDE drug therapy.

Also Known As:

Networked: 704 relevant articles (127 outcomes, 241 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	D'Incalci, Maurizio: 55 articles (01/2022 - 01/2002)
2.	Blay, Jean-Yves: 28 articles (01/2022 - 11/2005)
3.	Le Cesne, Axel: 24 articles (12/2020 - 07/2007)
4.	Sanfilippo, Roberta: 21 articles (01/2022 - 07/2007)
5.	D'Incalci, M: 21 articles (01/2018 - 05/2000)
6.	Frapolli, Roberta: 20 articles (01/2022 - 09/2003)
7.	Ray-Coquard, Isabelle: 17 articles (01/2022 - 10/2008)
8.	Gronchi, Alessandro: 17 articles (03/2021 - 07/2007)
9.	Jones, Robin L: 15 articles (03/2022 - 07/2007)
10.	Italiano, Antoine: 15 articles (01/2022 - 08/2011)

Related Diseases

1.	Sarcoma (Soft Tissue Sarcoma) 06/01/2012 - "Previous studies in sarcoma found that a composite gene signature, including high expression of nucleotide excision repair (NER) genes (XPG and/or ERCC1) and low expression of homologous recombination repair (HR) genes (BRCA1), identifies a highly sensitive population of patients with significantly improved outcome to trabectedin. " 01/01/2013 - "The present paper on a promising treatment with neoadjuvant trabectedin of patients with high-grade pleomorphic sarcoma might suggest that such treatment approach may provide a greater chance of cure and survival of such patients." 01/01/2013 - "This polymorphism was previously shown to be associated with better outcome in soft tissue sarcoma patients treated with trabectedin. " 01/01/2016 - "Trabectedin is reported to be particularly effective against translocation-related sarcoma. " 08/01/2014 - "Trabectedin may be especially effective against translocation-related sarcomas."
2.	Leiomyosarcoma 02/01/2019 - "[An Effective Treatment of Relapsed Leiomyosarcoma with Fourth-Line Trabectedin]." 12/01/2011 - "The aim of this retrospective analysis was to look at the efficacy of trabectedin in the subgroup of uterine leiomyosarcoma. " 01/01/2018 - "A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma." 01/01/2012 - "A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study." 01/01/2023 - "Long-Time Progression-Free Survival with Trabectedin in Chemorefractory Metastatic Leiomyosarcoma of the Retroperitoneum: A Case Report."
3.	Liposarcoma 01/01/2014 - "The present study describes a rare case of a mesenteric liposarcoma that resulted in a complete remission (CR) following treatment with trabectedin (Yondelis®). " 01/01/2014 - "Complete remission of a reccurrent mesenteric liposarcoma with rare histological features following the administration of trabectedin." 10/01/2016 - "Efficacy of trabectedin for the treatment of liposarcoma." 07/01/2014 - "The extraction recovery was >81% and the lower limit of quantification 0.025 ng/ml. The method was successfully applied to study trabectedin pharmacokinetics in a patient with a liposarcoma who received 1.3 mg/m² as a 24 h continuous i.v. infusion." 01/01/2014 - "In the present study, trabectedin was used for the treatment of a mesenteric liposarcoma of mixed morphological features and a CR was achieved."
4.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2007 - "The introduction of trabectedin expands the currently limited range of effective treatment options for patients with advanced or metastatic STS; trabectedin also has the potential to be a beneficial treatment for advanced or recurrent ovarian cancer." 02/01/2017 - "The efficacy of trabectedin in treating ovarian cancer." 01/01/2017 - "The aim of this study was to assess the efficacy and tolerability of trabectedin given every 10 days as a single agent in recurrent ovarian cancer after 3 prior regimens. " 01/01/2017 - "The MITO 15 was a prospective, single-arm trial, evaluating trabectedin monotherapy in patients with recurrent ovarian cancer (OC) who were BRCA mutation-carriers or had a BRCAness phenotype. " 03/01/2016 - "A prospective phase II trial was designed to evaluate the activity of trabectedin in the treatment of recurrent ovarian cancer patients presenting BRCA mutation and/or BRCAness phenotype. "
5.	Neoplasms (Cancer) 02/01/2001 - "A Phase II trial to assess the efficacy of ET-743 against this highly refractory neoplasm has been initiated on the basis of this observation. " 11/01/2021 - "In this study, we investigated whether treatment of tumor-bearing mice with trabectedin modulates the presence and functional activity of T-lymphocytes. " 01/01/2020 - "This study aimed to perform a time-lapse analysis of tumor response in patients with STS treated with trabectedin from 2 phase II clinical trials. " 01/01/2016 - "The efficacy and safety of trabectedin in pretreated patients with these tumors were evaluated in this parallel-cohort phase II trial. " 06/01/2013 - "Indeed, the unusual pattern of tumor response to trabectedin has raised queries about the appropriateness of conventional radiological evaluation of efficacy according to Response Evaluation Criteria in Solid Tumors and has prompted the search for new end points for Phase II studies. "

Related Drugs and Biologics

1.	Doxorubicin (Adriamycin)
2.	liposomal doxorubicin (Doxil)
3.	1-dodecylpyridoxal (PLD)
4.	Platinum
5.	Ifosfamide
6.	Trabectedin
7.	eribulin
8.	Anthracyclines
9.	Antineoplastic Agents (Antineoplastics)
10.	Irinotecan (Camptosar)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Intravenous Infusions
4.	Radiotherapy
5.	Cytoreduction Surgical Procedures